BioCryst Surpasses ORLADEYO Revenue Forecasts—2025 Net Sales Fuel Optimism for 2026
Growth Rate Exceeds Guidance as ORLADEYO Net Revenue Hits $601 Million
BioCryst Pharmaceuticals (Nasdaq: BCRX) has delivered a standout performance, reporting preliminary full-year 2025 ORLADEYO (berotralstat) net revenue of $601 million—a 37% increase year-over-year and ahead of previous guidance. Excluding European revenues, net sales jumped 43% on a comparable basis, illustrating robust demand and consistent execution in its core hereditary angioedema (HAE) market.
The company’s revenue not only beat its already elevated expectations ($590M–$600M guidance), but also underscored ORLADEYO's strong position as a leading oral, once-daily prophylactic for HAE. The sale of the European operations further sharpened BioCryst’s focus and financial flexibility moving into 2026.
2026 Guidance Signals Confidence—ORLADEYO Revenue Projected Up To $645 Million
Looking ahead, BioCryst expects 2026 global ORLADEYO net revenue to range between $625 million and $645 million, up to 7.3% higher than 2025. Including all products, total revenue is projected between $635 million and $660 million. These targets reflect both a solid patient demand trend and management's expectations for successful integration of new assets following the anticipated Astria Therapeutics acquisition.
| Financial Guidance Item | 2025 (Preliminary) | 2026 (Guidance) |
|---|---|---|
| ORLADEYO Net Revenue | $601 million | $625–$645 million |
| Total Revenue (Includes RAPIVAB) | — | $635–$660 million |
| Non-GAAP Operating Expense | — | $380–$390 million |
| Non-GAAP Operating Expense w/ Astria | — | $450–$470 million |
| Year-End Cash Position | $338 million | — |
Operational Efficiency and Astria Acquisition Drive Forward Strategy
Cost discipline is clear: non-GAAP operating expenses for 2026 are expected between $380 million and $390 million (excluding certain items). After the closing of the Astria deal—slated for Q1 2026—expenses should rise temporarily by $70 million to $80 million, primarily to fund late-stage development and manufacturing ramp for the pipeline. Management notes these incremental costs will trend down as operational synergies materialize and key trials conclude.
Sustained Profitability and Pipeline Progress Support Long-Term Growth
BioCryst projects continued non-GAAP profitability in 2026, even post-Astria acquisition. The company’s performance is further buoyed by its healthy cash reserves of $338 million at 2025 year-end, positioning it well for ongoing investment and risk management amid rare disease sector volatility.
Key Takeaway: Revenue Momentum and Strategic Focus Set the Stage for 2026
BioCryst’s ability to deliver 37% headline revenue growth (and 43% on a comparable basis) in 2025 reinforces its leadership in HAE and sets a high bar for the year ahead. With further upside guided for 2026, strategic moves such as the Astria acquisition, and a disciplined eye on expenses, investors and industry watchers alike may want to track BioCryst’s execution—and whether it can extend this momentum as the rare disease landscape evolves.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI